XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
Between March 30 and May 12, 2026, FDA district offices in Detroit, Nashville, Dallas, and the Los Angeles District's Owings Mills and Irvine field offices closed inspections at five independently operated compounding and outsourcing
View details →
Zenzi Pharmaceutical Industries Private Limited, a contract manufacturer located in Kudavali, Thane district, Maharashtra, India, is now carrying enforcement findings from two independent regulatory systems against the same physical site. The U.S. Food and
View details →
Bio-Thera Solutions Ltd.'s Yonghe manufacturing facility in Guangzhou, China, is now carrying a split GMP finding from the EU regulatory network. France's Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM)
View details → The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Statement of Non-Compliance with GMP against Geno Pharmaceuticals Private Limited's manufacturing site at Tivim Industrial Estate, Mapusa, Goa, India, following an unannounced
View details → Between April 14 and July 13, 2026, XGene tracked 14 international Good Manufacturing Practice (GMP) enforcement actions across the European Medicines Agency (EMA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) networks: 13
View details →
On June 22, 2026, the Food and Drug Administration (FDA) added Babikian Healthcare Products to Import Alert 66-40, the agency's Detention Without Physical Examination (DWPE) list for firms that have not met drug current
View details →
What FDA has not published alongside the listing is a specific deficiency narrative. IA 66-40 entries do not always carry one, and this is such a case: the Red List cites the standard "not
View details →
FDA's Pharmaceutical Quality–CMC structured data program has moved well past the pilot stage — the Stage 2 FHIR Implementation Guide cleared HL7 balloting in early 2025 and is now in active build toward a
View details → FDA Warning Letters to drug manufacturers rose roughly 50 to 59 percent year-over-year in FY2025 — and data integrity findings now appear in roughly 15 percent of all FY2025 Warning Letters, climbing to nearly
View details → Nitrosamine impurities defined a decade of pharmaceutical recalls and regulatory interventions beginning in 2018. The regulatory response — FDA and EMA directives requiring industry-wide risk assessments for all marketed products — created a CMC
View details → The back room during an FDA inspection is where the outcome is actually determined — the front room is where FDA asks the questions, but the back room is where your team decides what
View details → ICH Q3D established a risk-based framework for elemental impurity control that allows most pharmaceutical programs to avoid routine elemental testing if the risk assessment demonstrates that elemental impurity levels are well below the permitted
View details → FDA Warning Letters are the most detailed, most current, and most underutilized source of CMC and GMP competitive intelligence available to pharmaceutical companies — and the organizations that systematically mine this public database are
View details → ICH Q3C is one of the most frequently cited guidance documents in CDER chemistry deficiency letters, and most CMC teams believe they have implemented it correctly because they know the Class 1, 2, and
View details → Across hundreds of FDA Warning Letters issued to pharmaceutical manufacturers over the past five years, five quality system deficiency patterns appear with such regularity that they constitute a predictive model for where the next
View details →
Scale-up from kilogram to metric-ton synthesis is not a linear amplification. It is a process re-development exercise governed by physical chemistry — heat transfer coefficients that drop by a factor of 5–10 between a
View details → Most pharmaceutical manufacturers have a process validation Stage 3 Continued Process Verification program on paper — and most of those programs are generating data that no one is analyzing, producing control charts that no
View details → There are two moments in LNP manufacturing where the drug product is made. The one that actually determines the physical attributes of the particles you will release into patients is the moment the ethanol
View details →